{"id":"https://openalex.org/W104947592","doi":null,"title":"Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.","display_name":"Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.","publication_year":2007,"publication_date":"2007-01-01","ids":{"openalex":"https://openalex.org/W104947592","mag":"104947592","pmid":"https://pubmed.ncbi.nlm.nih.gov/17969373","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2291334"},"language":"en","primary_location":{"id":"pmh:oai:pubmedcentral.nih.gov:2291334","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2291334/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2291334/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vasc Health Risk Manag","raw_type":"Text"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2291334/pdf/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035281065","display_name":"Naylin Bissessor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801418622","display_name":"Auckland City Hospital","ror":"https://ror.org/05e8jge82","country_code":"NZ","type":"healthcare","lineage":["https://openalex.org/I2801418622","https://openalex.org/I4405259026"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Naylin Bissessor","raw_affiliation_strings":["Green Lane Cardiovascular Research Unit,Auckland City Hospital, Auckland, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Green Lane Cardiovascular Research Unit,Auckland City Hospital, Auckland, New Zealand","institution_ids":["https://openalex.org/I2801418622"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062843291","display_name":"Harvey Douglas White","orcid":"https://orcid.org/0000-0001-7712-6750","observed_orcids":["https://orcid.org/0000-0001-7712-6750"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Harvey White","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8927,"has_fulltext":true,"cited_by_count":20,"citation_normalized_percentile":{"value":0.77389649,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"3","issue":"4","first_page":"425","last_page":"30"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9595000147819519,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9595000147819519,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.026799999177455902,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11962","display_name":"Cardiac Fibrosis and Remodeling","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valsartan","display_name":"valsartan","score":1.0},{"id":"https://openalex.org/keywords/heart-failure","display_name":"heart failure","score":0.7630000114440918},{"id":"https://openalex.org/keywords/left-ventricular-dysfunction","display_name":"left ventricular dysfunction","score":0.9950000047683716},{"id":"https://openalex.org/keywords/myocardial-infarction","display_name":"myocardial infarction","score":0.953000009059906},{"id":"https://openalex.org/keywords/renin-angiotensin-aldosterone-system","display_name":"renin-angiotensin-aldosterone system","score":0.9340000152587891},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.878000020980835},{"id":"https://openalex.org/keywords/ace-inhibitors","display_name":"ACE inhibitors","score":0.8650000095367432},{"id":"https://openalex.org/keywords/captopril","display_name":"captopril","score":0.9409999847412109},{"id":"https://openalex.org/keywords/valiant-trial","display_name":"VALIANT trial","score":0.9210000038146973},{"id":"https://openalex.org/keywords/cardiac-remodeling","display_name":"cardiac remodeling","score":0.7829999923706055},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8899999856948853},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.5189999938011169},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.9129999876022339}],"concepts":[{"id":"https://openalex.org/C2777387769","wikidata":"https://www.wikidata.org/wiki/Q155472","display_name":"Valsartan","level":3,"score":0.9174105525016785},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9139323234558105},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.7843829393386841},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.7463048100471497},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7015557289123535},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.6702848076820374},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.5745241641998291},{"id":"https://openalex.org/C2779611605","wikidata":"https://www.wikidata.org/wiki/Q288280","display_name":"ACE inhibitor","level":4,"score":0.53243488073349},{"id":"https://openalex.org/C2779479957","wikidata":"https://www.wikidata.org/wiki/Q421119","display_name":"Captopril","level":3,"score":0.5298830270767212},{"id":"https://openalex.org/C123915805","wikidata":"https://www.wikidata.org/wiki/Q15332826","display_name":"Angiotensin II receptor type 1","level":4,"score":0.5156108736991882},{"id":"https://openalex.org/C27016395","wikidata":"https://www.wikidata.org/wiki/Q128861","display_name":"Angiotensin-converting enzyme","level":3,"score":0.4552608132362366},{"id":"https://openalex.org/C2776002628","wikidata":"https://www.wikidata.org/wiki/Q1628627","display_name":"Left ventricular hypertrophy","level":3,"score":0.4535272717475891},{"id":"https://openalex.org/C2779537366","wikidata":"https://www.wikidata.org/wiki/Q7920323","display_name":"Ventricular remodeling","level":3,"score":0.4502815008163452},{"id":"https://openalex.org/C104849204","wikidata":"https://www.wikidata.org/wiki/Q24778533","display_name":"Angiotensin receptor","level":4,"score":0.44692039489746094},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.20369595289230347}],"mesh":[{"descriptor_ui":"D000068756","descriptor_name":"Valsartan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000804","descriptor_name":"Angiotensin II","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D000806","descriptor_name":"Angiotensin-Converting Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006333","descriptor_name":"Heart Failure","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009203","descriptor_name":"Myocardial Infarction","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D012084","descriptor_name":"Renin-Angiotensin System","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018487","descriptor_name":"Ventricular Dysfunction, Left","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":5,"locations":[{"id":"pmh:oai:pubmedcentral.nih.gov:2291334","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2291334/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2291334/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vasc Health Risk Manag","raw_type":"Text"},{"id":"pmid:17969373","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17969373","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vascular health and risk management","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:9d4bfcf02c76445d9fa96a75f73aae40","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/9d4bfcf02c76445d9fa96a75f73aae40","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Vascular Health and Risk Management, Vol Volume 3, Pp 425-430 (2007)","raw_type":"article"},{"id":"pmh:oai:research-repository.griffith.edu.au:10072/27476","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/10072/27476","pdf_url":null,"source":{"id":"https://openalex.org/S7407064376","display_name":"Griffith Research Online","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Journal article"},{"id":"mag:104947592","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17969373","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:2291334","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2291334/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2291334/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vasc Health Risk Manag","raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W104947592.pdf","grobid_xml":"https://content.openalex.org/works/W104947592.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W153351502","https://openalex.org/W1777805768","https://openalex.org/W1987093417","https://openalex.org/W2007068948","https://openalex.org/W2011563843","https://openalex.org/W2014899753","https://openalex.org/W2020103404","https://openalex.org/W2021011733","https://openalex.org/W2021671593","https://openalex.org/W2023849708","https://openalex.org/W2032872502","https://openalex.org/W2039055647","https://openalex.org/W2049952152","https://openalex.org/W2056893352","https://openalex.org/W2078757161","https://openalex.org/W2091744415","https://openalex.org/W2096682768","https://openalex.org/W2098780362","https://openalex.org/W2099644064","https://openalex.org/W2107471172","https://openalex.org/W2110831147","https://openalex.org/W2122340355","https://openalex.org/W2132697533","https://openalex.org/W2141716584","https://openalex.org/W2147615829","https://openalex.org/W2168651123","https://openalex.org/W2168907840","https://openalex.org/W2323072331","https://openalex.org/W2571240023"],"related_works":["https://openalex.org/W2160305626","https://openalex.org/W2316994246","https://openalex.org/W2946279320","https://openalex.org/W2055481333","https://openalex.org/W2095862019","https://openalex.org/W2371936526","https://openalex.org/W2056362163","https://openalex.org/W2033202346","https://openalex.org/W2168651123","https://openalex.org/W2149523545"],"abstract_inverted_index":{"The":[0,19,131,172],"physiological":[1],"role":[2,196],"of":[3,15,21,58,97,108,117,139,197],"the":[4,13,16,27,59,86,95,98,109,140,166,195,216],"renin":[5],"angiotensin":[6,22,28,62,110],"aldosterone":[7],"system":[8],"(RAAS)":[9],"is":[10,24],"to":[11,50,74,124,154],"maintain":[12],"integrity":[14],"cardiovascular":[17,76],"system.":[18],"effect":[20],"II":[23],"mediated":[25],"via":[26],"type":[29],"I":[30],"receptor":[31,81,111],"(AT1":[32],")":[33],"resulting":[34],"in":[35,101,165,188,199,215],"vasoconstriction,":[36],"sodium":[37],"retention":[38],"and":[39,55,78,121,137,186,213],"myocyte":[40],"growth":[41],"changes.":[42],"This":[43,192],"causes":[44],"myocardial":[45,69,103,169,204],"remodeling":[46],"which":[47],"eventually":[48],"leads":[49,123],"left":[51,159,200],"ventricular":[52,160,201],"hypertrophy,":[53],"dilation":[54],"dysfunction.":[56],"Inhibition":[57],"RAAS":[60],"with":[61,112,147,158],"converting":[63],"enzyme":[64],"(ACE)":[65],"inhibitors":[66],"after":[67],"acute":[68,102],"infarction":[70,104,170],"has":[71,90],"been":[72,92],"shown":[73],"reduce":[75],"morbidity":[77],"mortality.":[79],"Angiotensin":[80],"blockers":[82],"(ARBs)":[83],"specifically":[84],"inhibit":[85],"AT1":[87],"receptor.":[88],"It":[89],"not":[91],"known":[93],"until":[94],"performance":[96],"VALIANT":[99,132],"(valsartan":[100],"trial)":[105],"whether":[106],"blockade":[107],"an":[113,118,128,183],"ARB":[114,122,141,184],"or":[115,162,182],"combination":[116,173],"ACE":[119,129,180],"inhibitor":[120],"similar":[125],"outcomes":[126],"as":[127],"inhibitor.":[130],"trial":[133],"demonstrated":[134],"equal":[135],"efficacy":[136],"non-inferiority":[138],"valsartan":[142,198],"160":[143],"mg":[144,150],"bid":[145],"compared":[146],"captopril":[148],"50":[149],"tds,":[151],"when":[152],"administered":[153],"high":[155],"risk":[156],"patients":[157],"dysfunction":[161,202],"heart":[163],"failure":[164],"immediate":[167],"post":[168,203],"period.":[171],"therapy":[174],"showed":[175],"no":[176],"incremental":[177],"benefit":[178],"over":[179],"inhibition":[181],"alone":[185],"resulted":[187],"increased":[189],"adverse":[190],"effects.":[191],"review":[193],"examines":[194],"infarction.":[205],"We":[206],"also":[207],"discuss":[208],"pharmacokinetics,":[209],"dosing,":[210],"side":[211],"effects,":[212],"usage":[214],"elderly.":[217]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":6}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2016-06-24T00:00:00"}